Phase I/II Trial: GDC-7035 in KRAS G12D-Mutant Advanced Solid Tumors

Genentech, Inc. is conducting a first-in-human, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of GDC-7035—a KRAS (G12D) inhibitor—administered both as a single agent and in combination with other therapies in patients with advanced or metastatic solid tumors harboring this mutation. The trial includes two dose-escalation and expansion arms to optimize dosing and activity.